BeOne Medicines reports new Phase 1 results across three liver and lung cancer programmes
BeOne reports new liver and lung cancer responses across three Phase 1 drugs, but dosing, safety and confirmatory evidence will shape development.
Pharma & Biotech
Pharma & Biotech
Ziihera extends overall survival versus trastuzumab in Phase 3 first-line HER2-positive gastroesophageal cancer trial
Jazz Pharmaceuticals says a second interim analysis of HERIZON-GEA-01 found statistically significant and clinically meaningful overall survival improvement with Ziihera plus chemotherapy versus trastuzumab plus chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinoma.
Pharma & Biotech
Jazz wins first-line Ziihera approval as HERIZON-GEA-01 resets the HER2 treatment benchmark
FDA has approved two Ziihera-based first-line regimens in HER2-positive advanced gastroesophageal adenocarcinoma after the Tevimbra combination improved median overall survival from 19.2 to 26.4 months.
Pharma & Biotech
Could BeOne’s zanidatamab regimen reset expectations in HER2-positive gastroesophageal cancer?
Find out how BeOne’s HERIZON-GEA data could reshape HER2-positive gastroesophageal cancer treatment after ASCO 2026.